OSR Holdings Files 8-K: Regulation FD, Other Events
Ticker: OSRHW · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1840425
| Field | Detail |
|---|---|
| Company | Osr Holdings, Inc. (OSRHW) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $20M, $815M |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, company-update
TL;DR
OSR Holdings dropped an 8-K on Nov 25th covering Reg FD, other events, and financials. Check it out.
AI Summary
OSR Holdings, Inc. filed an 8-K on November 25, 2025, reporting events as of November 21, 2025. The filing indicates a Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. The company, formerly known as Bellevue Life Sciences Acquisition Corp., is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides updates on important company events and disclosures, which are crucial for investors to understand the current status and potential implications for OSR Holdings.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine events and disclosures, not indicating any immediate significant financial distress or major operational changes.
Key Players & Entities
- OSR Holdings, Inc. (company) — Registrant
- Bellevue Life Sciences Acquisition Corp. (company) — Former company name
- November 21, 2025 (date) — Earliest event reported date
- November 25, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific events are covered under 'Regulation FD Disclosure' and 'Other Events' in this 8-K filing?
The provided text does not detail the specific content of the Regulation FD Disclosure or Other Events, only that these items are included in the filing.
When was OSR Holdings, Inc. formerly known as Bellevue Life Sciences Acquisition Corp. and when did the name change occur?
The filing states the former company name was Bellevue Life Sciences Acquisition Corp. and the date of the name change was January 13, 2021.
What is the business address and phone number for OSR Holdings, Inc.?
The business address is 10900 NE 4TH STREET, SUITE 2300, BELLEVUE, WA 98004, and the business phone number is 425-635-7700.
What is the SIC code for OSR Holdings, Inc. and what industry does it represent?
The Standard Industrial Classification (SIC) code is 3841, which represents 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS'.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 21, 2025.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-25 10:56:22
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share OSRH The Nasdaq Stock Mar
- $11.50 — of common stock at an exercise price of $11.50 per share OSRHW The Nasdaq Stock Ma
- $20M — Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones."
- $815M — M01 License with $20M Upfront and Up to $815M in Milestones." 104 Cover Page Inte
Filing Documents
- ea0267127-8k_osrhold.htm (8-K) — 33KB
- ea026712701ex10-1_osrhold.htm (EX-10.1) — 62KB
- ea026712701ex99-1_osrhold.htm (EX-99.1) — 11KB
- 0001213900-25-114496.txt ( ) — 326KB
- osrh-20251121.xsd (EX-101.SCH) — 4KB
- osrh-20251121_def.xml (EX-101.DEF) — 26KB
- osrh-20251121_lab.xml (EX-101.LAB) — 36KB
- osrh-20251121_pre.xml (EX-101.PRE) — 25KB
- ea0267127-8k_osrhold_htm.xml (XML) — 6KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On November 21, 2025, the Company issued a press release announcing that its Swiss-based subsidiary, Vaximm AG, entered into a global license term sheet with BCM Europe AG for the VXM01 oral immunotherapy platform. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
01. Other Events
Item 8.01. Other Events On November 21, 2025, Vaximm AG, a Swiss-based subsidiary of OSR Holdings, Inc., entered into a non-binding Global License Agreement Term Sheet with BCM Europe AG ("BCME"), the largest shareholder of the Company. The Term Sheet outlines the principal terms under which Vaximm and BCME intend to negotiate a definitive global license agreement relating to the Company's VXM01 oral cancer immunotherapy platform. The Term Sheet includes an exclusivity period for negotiations and certain binding provisions, but does not constitute a definitive agreement and does not impose material obligations on the Company at this stage. A copy of the Term Sheet is filed as Exhibit 10.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits EXHIBIT INDEX Exhibit No. Description 10.1 Global License Agreement Term Sheet, dated November 21, 2025, between Vaximm AG and BCM Europe AG 99.1 Press Release dated November 21, 2025 titled "Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 25, 2025 OSR HOLDINGS, INC. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer 2